Acquisition Pivots this Firm to Psychedelic Drug Development

Acquisition Pivots this Firm to Psychedelic Drug Development

By: Dylan Sikes – News

Thursday, January 20, 2022

The exploration of psychedelics for mental health treatment is a growing opportunity and this firm is ceasing its current operations to focus on drug development with its new acquisition. 

Blue Water Ventures International, Inc. (OTCPK: BWVI) is changing its objective following the acquisition of  Psycheceutical, Inc., a biotechnology company dedicated to the development and commercialization of psychedelic medicines.

Though a merger, BWVI acquired Psycheceutical, Inc. which resulted in Psycheceutical becoming a wholly-owned subsidiary of BWVI, per the company’s press release. Following all necessary regulatory approvals, the company will proceed with a name and symbol change.

Psycheceutical brings a team with over 100 years' combined experience in development, regulatory approval processes and commercialization across the pharmaceutical industry.

Shares of BWVI were trading down at $0.58 in afternoon trade. 

Copyright © 2021 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Improving Air Safety and Disrupting the Air Treatment Industry
Walking the Walk, This Penny Stock Crushing It In 2022
Leading Cannabis Accessory Distributor Announces Q3 Results and Rapid Expansion into California
Most Popular
FREE Newsletter

Back to Top